Literature DB >> 31344512

Computer-assisted engineering of programmed drug releasing multilayer nanomedicine via indomethacin-mediated ternary complex for therapy against a multidrug resistant tumor.

Ling Che1, Zhirui Liu2, Dong Wang1, Chunmei Xu3, Chengyuan Zhang3, Jin Meng1, Jun Zheng1, Hongfeng Yuan4, Guanren Zhao5, Xing Zhou6.   

Abstract

Nanomedicine with programmed drug release can give full play to the synergistic effect of multi-component system in complicated tumor environment. However, the construction of these programmed drug delivery systems often depends on the sophisticated materials design and synthesis. In this study, we successfully designed an indomethacin (IND)-mediated ternary complex system based on a PEG cleavable polyethyleneimine (PEI), indomethacin (IND) and benzene ring containing chemotherapeutic drugs (such as paclitaxel (PTX), doxorubicin and docetaxel). Based on the difference of hydrophobicity in these components, these components were one-pot self-assembled into drug-loaded IND mediated PEGylation cleavable nanoassemblies (IPCNs) in multilayer structure. In drug-loaded IPCNs, PEG fragments, PEI/IND, and chemotherapeutic drug were respectively distributed from the out layer to core of nanomedicine. When drug-loaded IPCNs reached tumor site through EPR effect, the PEG fragment would firstly responsively release to the acidic tumor microenvironment to expose the intermediate layer of drug-loaded IPCNs that composed by mixture of PEI and IND for increasing the surface potential to promote the uptake by tumor cells. After entering cells, IND would be released faster than chemotherapeutic drug encapsulated in core to efficiently inhibit the expression of multidrug resistance protein 1 to reverse MDR of tumor cells before chemotherapeutic drug releasing. Contributed by the staged responsively releasing of PEG fragments, IND and encapsulated chemotherapeutic drug, the drug-loaded IPCNs exhibited a superior antitumor efficacy against A549/MDR tumor cells both in vitro and in vivo. STATEMENT OF SIGNIFICANCE: The way to develop programmed released drug delivery system is commonly relied on complicated material design and synthesis. Herein, under the computer-assist design, we successfully designed a ternary complex derived from indomethacin (IND), paclitaxel (PTX) and a pH-responsive PEGylated polyethyleneimine (PEG-s-PEI), and employed this ternary complex to successfully prepare a high drug loading and multilayer structured nanomedicine of PTX (PTX IPCNs). Contribute by the different location of PTX, IND and PEG-s-PEI in PTX IPCNs, PEG fragments, IND and PTX molecules could programmed release after reaching tumor for perfectly realizing the synergistic anti-tumor effect of tumor targeting, reversal of MDR and chemotherapy. Based on a fusion of these multiple mechanisms, PTX IPCNs showed a superior antitumor efficacy in mice loading A549/MDR tumor.
Copyright © 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Controlled release; Multidrug resistance; Multilayer nanomedicines; Self-assembly; Targeted delivery

Year:  2019        PMID: 31344512     DOI: 10.1016/j.actbio.2019.07.033

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  6 in total

1.  Adjudin-loaded redox-sensitive paclitaxel-prodrug micelles for overcoming multidrug resistance with efficient targeted Colon cancer therapy.

Authors:  Deli Chen; Sitang Ge; Lugen Zuo; Shuanhu Wang; Mulin Liu; Shiqing Li
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

Review 2.  Recent Progress of Novel Nanotechnology Challenging the Multidrug Resistance of Cancer.

Authors:  Chengyuan Zhang; Xuemei Zhou; Hanyi Zhang; Xuanliang Han; Baijun Li; Ran Yang; Xing Zhou
Journal:  Front Pharmacol       Date:  2022-02-14       Impact factor: 5.810

3.  Hyaluronic acid reduction-sensitive polymeric micelles achieving co-delivery of tumor-targeting paclitaxel/apatinib effectively reverse cancer multidrug resistance.

Authors:  Xiaoqing Zhang; Xiaomei Ren; Jiayin Tang; Jiangtao Wang; Xiang Zhang; Peng He; Chang Yao; Weihe Bian; Lizhu Sun
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

4.  A pH/ROS cascade-responsive and self-accelerating drug release nanosystem for the targeted treatment of multi-drug-resistant colon cancer.

Authors:  Na Chang; Yufei Zhao; Ning Ge; Liting Qian
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.819

5.  Prevention of Obesity Related Diseases through Laminarin-induced targeted delivery of Bindarit.

Authors:  Chunmei Xu; Luqi Yin; Zhipeng Teng; Xuemei Zhou; Wenjie Li; Qiong Lai; Cuiping Peng; Chengyuan Zhang; Jie Lou; Xing Zhou
Journal:  Theranostics       Date:  2020-07-25       Impact factor: 11.556

6.  Resveratrol-Loaded TPGS-Resveratrol-Solid Lipid Nanoparticles for Multidrug-Resistant Therapy of Breast Cancer: In Vivo and In Vitro Study.

Authors:  Wenrui Wang; Mengyang Zhou; Yang Xu; Wei Peng; Shiwen Zhang; Rongjie Li; Han Zhang; Hui Zhang; Shumin Cheng; Youjing Wang; Xinyu Wei; Chengxu Yue; Qingling Yang; Changjie Chen
Journal:  Front Bioeng Biotechnol       Date:  2021-12-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.